莫西沙星治疗复治菌阳性肺结核探讨

Clinical effect of moxifloxacin in the treatment of first retreated pulmonary tuberculosis

目的探讨莫西沙星治疗复治菌阳性肺结核临床效果。方法选取复治菌阳性肺结核患者80例,随机分为对照组(40例)和观察组(40例),分别在标准抗结核方案基础上加用左氧氟沙星和莫西沙星治疗;比较两组患者疗效。结果观察组患者临床治愈率、痰菌转阴率、空洞闭合率及肺内病灶吸收率均显著高于对照组(P<0.05);观察组患者治疗后SF-12生活质量评价量表评分显著高于对照组(P<0.05);两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论莫西沙星治疗复治菌阳性肺结核效果优于标准抗痨方案,具有临床应用价值。

Objective To investigate the clinical effect of moxifloxacin in the treatment of first retreated pul-monary tuberculosis. Methods 80 patients with first retreated pulmonary tuberculosis were chosen and randomly di-vided into two groups. The control group （40 patients） was given levofloxacin, and the observation group （40 pa-tients） was given moxifloxacin, on the basis of standard anti-tuberculosis scheme. The clinical effect of both groups were compared. Results The clinical cure rate, the sputum negative rate, cavity closure rate and focus absorption rate of the observation group were significant better than those in the control group （P〈0. 05）. The SF-12 life quali-ty evaluation scale score after treatment was significant better in the observation group than in the control group （ P〈0. 05）. There was no significant difference in adverse effect between the two groups （P〉0. 05）. Conclusion On the basis of standard anti-tuberculosis scheme, moxifloxacin has better clinical effect in the treatment of first retreated pulmonary tuberculosis.